Oragenics, Inc.
Oragenics, Inc. (OGEN) is a Biotechnology company in the Healthcare sector, listed on New York Stock Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Oragenics, Inc. in 2026.
Earnings calendar
Next earnings date
—
Not scheduled
EPS estimate
—
Revenue estimate
—
Past earnings
No earnings history available.
Dividend calendar
No dividend history available.
Company profile
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Exchange
- New York Stock Exchange
- CEO
- Janet Huffman
- Employees
- 3
- IPO date
- 25 Feb 2004
- ISIN
- US6840236094
- Website
- oragenics.com
Frequently asked questions
Where is Oragenics, Inc. stock listed?
Oragenics, Inc. (OGEN) is listed on New York Stock Exchange.